Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females of child-bearing potential must be using and are willing to continue using effective birth control methods, or be willing to practice sexual abstinence throughout treatment or be nonheterosexual active~* Confirmed pulmonary MDR-TB infection including those infected with XDR (extensively drug resistant)-TB~* Positive for acid-fast bacilli (AFB) on direct smear examination of expectorated sputum specimen (= 1+ smear-positive)~* HIV-positive patients are eligible, provided they meet the requirements as described in the protocol~* Must voluntarily sign the Informed Consent Form (ICF) prior to starting any study activities~* Willing to comply with protocol requirements~* Willing to comply with NTP treatment guidelines~Exclusion Criteria:~* Patients having a known or suspected hypersensitivity or serious adverse reaction to TMC207~* Patients with significant cardiac arrhythmia requiring medication~* Patients with complicated or severe extrapulmonary manifestations of TB, including central nervous system infection~* Patients with certain QT/QTc interval characteristics as described in the protocol~* Patients having participated in other clinical studies with investigational agents, within 8 weeks prior to trial start~* Women who are pregnant or breastfeeding~* Patients who have previously received treatment with TMC207 as part of a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMC207 (Type: EXPERIMENTAL): TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks in addition to Background Regimen (BR) for the treatment of multi-drug resistant tuberculosis (MDR-TB).

Based on this trial design, predict the completion outcome and termination type (if applicable).